ASCO 2023 | Response to neoadjuvant ICI-based therapy in oncogene-driven resectable NSCLC

Samuel Rosner, MD, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, provides an overview of an investigation into the response to neoadjuvant immune checkpoint inhibitor (ICI)-based therapy in oncogene-driven resectable non-small cell lung cancer (NSCLC). Genomic profiling using next-generation sequencing was conducted, and patients with specific alterations in genes such as KRAS, EGFR, MET, BRAF, ALK, HER2, ROS1, RET, or NTRK were identified as having oncogene-driven NSCLC (OD-NSCLC). The majority of patients in the cohort had KRAS mutations. The study found comparable recurrence-free survival (RFS) between OD-NSCLC and non-OD-NSCLC patients, including those with KRAS+ disease. However, patients with KRAS+ tumors had lower rates of major pathologic response (MPR). The presence of STK11 mutations and co-alterations with KRAS trended toward shorter RFS. The study emphasizes the need for larger cohorts and standardized treatment approaches to draw definitive conclusions. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.